ARCHIVES

Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.

This article is from The Cancer Letter archive.

Vol. 31 No. 01 | January 7, 2005

Download PDF Visit The Full Archive

Related Articles

In Brief: George Vande Woude Of NCI Named PI for Litton Bionetics Basic Research Contract At Frederick

September 23, 1983

In Brief: USC Study Finds Sedentary Occupations Increase Colon Cancer Risk for Men Over More Active Jobs

November 30, 1984

NCAB Considering Concept Review Of Large, Expensive Investigator Initiated Proposals

February 16, 1990

AACR Journal Publishes a Henschke Letter Without Disclosure of Conflicts.

April 25, 2008

NCAB ‘Incredulous’ Over Proposed Ethics Rules, Bard Members Threaten Resignation In Letter

October 4, 1991

James Watkins To Head AIDS Commission Following Mayberry’s Resignation

October 16, 1987